Therapeutic targets for metastatic prostate cancer

被引:18
作者
Timme, TL
Satoh, T
Tahir, SA
Wang, HY
Teh, BS
Butler, EB
Miles, BJ
Amato, RJ
Kadmon, D
Thompson, TC
机构
[1] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA
[2] Vet Affairs Med Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
关键词
gene therapy; immunotherapy; antibody therapy; RTVP-1; caveolin-1; interleukin-12; HSV-tk;
D O I
10.2174/1389450033491127
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in adult males. Although prostate cancer that is confined to the gland can be cured in many patients using surgery or radiation, these treatments are only effective for localized tumors and the long-term failure rates for these treatments suggests that prostate cancer can metastasize relatively early in the course of the disease. Once prostate cancer has metastasized there are no curative therapies. The greatest challenge in the treatment of advanced prostate cancer is to access and eliminate metastatic cells. Therefore, effective prostate cancer therapy will require novel strategies to target cancer cells both at the site of the primary tumor and at distant metastatic sites. In this article we review several therapeutic targets and approaches that may provide new treatments for metastatic prostate cancer. We discuss the use of small molecules to target specific molecular events associated with metastatic prostate cancer, the use of specific antibodies that target unique metastasis associated molecules and the use of various gene therapy strategies to achieve anti-metastatic activities.
引用
收藏
页码:251 / 261
页数:11
相关论文
共 115 条
[1]   Development of the proteasome inhibitor PS-341 [J].
Adams, J .
ONCOLOGIST, 2002, 7 (01) :9-16
[2]  
Agus DB, 1999, CANCER RES, V59, P4761
[3]   Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer [J].
Atkinson, G ;
Hall, SJ .
UROLOGY, 1999, 54 (06) :1098-1104
[4]   Cytopathic effect of in situ gene therapy in prostate cancer [J].
Ayala, G ;
Wheeler, TM ;
Shalev, M ;
Thompson, TC ;
Miles, B ;
Aguilar-Cordova, E ;
Chakraborty, S ;
Kadmon, D .
HUMAN PATHOLOGY, 2000, 31 (07) :866-870
[5]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[6]  
Burch PA, 2000, CLIN CANCER RES, V6, P2175
[7]   Enhanced therapeutic effect of HSV-tk plus GCV gene therapy and ionizing radiation for prostate cancer [J].
Chhikara, M ;
Huang, HX ;
Vlachaki, MT ;
Zhu, XH ;
Teh, B ;
Chiu, KJ ;
Woo, S ;
Berner, B ;
Smith, EO ;
Oberg, KC ;
Aguilar, LK ;
Thompson, TC ;
Butler, EB ;
Aguilar-Cordova, E .
MOLECULAR THERAPY, 2001, 3 (04) :536-542
[8]   RESULTS OF CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER [J].
CHODAK, GW ;
THISTED, RA ;
GERBER, GS ;
JOHANSSON, JE ;
ADOLFSSON, J ;
JONES, GW ;
CHISHOLM, GD ;
MOSKOVITZ, B ;
LIVNE, PM ;
WARNER, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) :242-248
[9]   Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter [J].
Cleutjens, KBJM ;
vanEekelen, CCEM ;
vanderKorput, HAGM ;
Brinkmann, AO ;
Trapman, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6379-6388
[10]   Tumor immunotherapy: inching toward the finish line [J].
Curiel, TJ ;
Curiel, DT .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :311-312